Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
Rhea-AI Summary
Biofrontera (Nasdaq: BFRI), a biopharmaceutical company focused on PDT development and commercialization, will release its financial results for Q3 2024 and the nine months ended September 30, 2024, after market close on November 13, 2024. The company will host a conference call to discuss the results on November 14, 2024, at 10:00 AM ET. The call will be accessible via phone and webcast for both U.S. and international participants.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BFRI declined 11.38%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WOBURN, MA / ACCESSWIRE / November 1, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of PDT, announces it will report financial results for the three and nine months ended September 30, 2024 on Wednesday, November 13, 2024. The results will be released after the market close on Wednesday, Nov 13 and the company will host a conference call on Thursday, November 14 at 10:00am Eastern Time.
Conference Call and Webcast Information
Event: | Biofrontera Inc. Third Quarter 2024 Financial Results and Business Update Conference Call |
Date: | Thursday, November 14, 2024 |
Time: | 10:00am ET |
Conference Call: | 1-877-877-1275 (U.S.) 1-412-858-5202 (international) |
Webcast: | Webcast | Third Quarter 2024 Financial Results and Business Update Conference Call |
About Biofrontera Inc.
Biofrontera is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of Actinic Keratosis, pre-cancerous skin lesions which may progress to invasive skin cancers1. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.
1 - https://www.skincancer.org/skin-cancer-information/actinic-keratosis/
Contacts:
Investor Relations
Andrew Barwicki
1-516-662-9461
ir@bfri.com
SOURCE: Biofrontera Inc.
View the original press release on accesswire.com
FAQ
When will Biofrontera (BFRI) release Q3 2024 earnings?
When is Biofrontera's (BFRI) Q3 2024 earnings call?
How can I access Biofrontera's (BFRI) Q3 2024 earnings call?
